$LEXX
Lexaria Bioscience Corp. Stock $lexx

$lexx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000164033422002512 Filed on November 28, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022
Revenue	$101.5K	$111.2K	$255.4K
YoY Change	631.1%	258.32%	-64.66%
Cost Of Revenue	$15.80K	$41.25K	$71.84K
YoY Change	183.57%	103.1%	-59.03%
Gross Profit	$85.68K	$69.90K	$183.6K
YoY Change	931.06%	552.66%	-66.47%
Gross Profit Margin	84.43%	62.89%	71.87%
Selling, General & Admin	$1.026M	$1.227M	$5.725M
YoY Change	-33.97%	39.35%	19.13%
% of Gross Profit	1196.88%	1755.18%	3118.68%
Research & Development	$829.5K	$356.2K	$1.843M
YoY Change	80.83%	-19.01%	45.91%
% of Gross Profit	968.11%	509.57%	1003.88%
Depreciation & Amortization	$24.73K	$24.73K	$102.7K
YoY Change	-11.46%	-11.46%	-8.05%
% of Gross Profit	28.86%	35.38%	55.96%
Operating Expenses	$1.855M	$1.583M	$7.567M
YoY Change	304.39%	28.29%	21.38%
Operating Profit	-$1.769M	-$1.513M	-$7.384M
YoY Change	292.83%	23.7%	29.84%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$73.89K		-$764.6K
YoY Change
Pretax Income	-$1.769M	-$1.513M	-$7.384M
YoY Change	-11.69%	16.16%	77.07%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.756M	-$1.467M	-$7.269M
YoY Change	-12.36%	24.56%	73.65%
Net Earnings / Revenue	-1730.4%	-1320.26%	-2846.28%
Basic Earnings Per Share
Diluted Earnings Per Share	-$295.1K	-$246.6K	-$1.235M
COMMON SHARES
Basic Shares Outstanding	5.951M shares	5.951M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.803M	$5.931M	$6.161M
YoY Change	-52.8%	-49.53%	-47.58%
Cash & Equivalents	$4.533M	$5.813M
Short-Term Investments	$269.7K	$118.2K	$347.3K
Other Short-Term Assets	$260.3K	$576.8K	$576.8K
YoY Change	9.75%	80.66%	80.66%
Inventory	$9.936K	$38.42K	$38.42K
Prepaid Expenses	$260.3K	$576.8K
Receivables	$286.3K	$201.8K	$80.37K
Other Receivables	$149.3K	$121.4K	$121.4K
Total Short-Term Assets	$5.359M	$6.978M	$6.978M
YoY Change	-50.84%	-43.92%	-43.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$311.2K	$315.5K	$368.0K
YoY Change	-33.19%	-14.31%	-19.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$854.1K	$856.4K	$856.4K
YoY Change	1.13%	3.95%	3.95%
TOTAL ASSETS
Total Short-Term Assets	$5.359M	$6.978M	$6.978M
Total Long-Term Assets	$854.1K	$856.4K	$856.4K
Total Assets	$6.213M	$7.834M	$7.834M
YoY Change	-47.1%	-40.95%	-40.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$173.7K	$57.15K	$57.15K
YoY Change	0.46%	4.54%	4.54%
Accrued Expenses	$107.8K	$136.9K	$136.9K
YoY Change	89.19%	60.18%	60.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$281.5K	$194.0K	$194.0K
YoY Change	18.44%	26.59%	26.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$7.400K	$7.400K
YoY Change	-100.0%	-85.2%	-85.2%
Total Long-Term Liabilities	$0.00	$7.401K	$7.400K
YoY Change	-100.0%	-85.19%	-85.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$281.5K	$194.0K	$194.0K
Total Long-Term Liabilities	$0.00	$7.401K	$7.400K
Total Liabilities	$281.5K	$201.4K	-$115.0K
YoY Change	1.51%	-0.9%	-9844.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.85M	-$39.10M
YoY Change	20.79%	22.84%
Common Stock	$5.951K	$5.951K
YoY Change	3.91%	3.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.262M	$7.949M	$7.949M
YoY Change
Total Liabilities & Shareholders Equity	$6.213M	$7.834M	$7.834M
YoY Change	-47.1%	-40.95%	-40.95%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022
OPERATING ACTIVITIES
Net Income	-$1.756M	-$1.467M	-$7.269M
YoY Change	-12.36%	24.56%	73.65%
Depreciation, Depletion And Amortization	$24.73K	$24.73K	$102.7K
YoY Change	-11.46%	-11.46%	-8.05%
Cash From Operating Activities	-$1.234M	-$1.177M	-$4.879M
YoY Change	5.81%	1.24%	22.3%
INVESTING ACTIVITIES
Capital Expenditures	$20.50K	-$50.04K	-$180.6K
YoY Change	-135.21%		127.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$34.84K	-$50.04K	-$180.6K
YoY Change	-40.15%		-193.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	-$11.20K	-11.20K	-$44.60K
YoY Change	1.98%	-100.28%	-100.33%
NET CHANGE
Cash From Operating Activities	-$1.234M	-1.177M	-$4.879M
Cash From Investing Activities	-$34.84K	-50.04K	-$180.6K
Cash From Financing Activities	-$11.20K	-11.20K	-$44.60K
Net Change In Cash	-$1.280M	-1.238M	-$5.105M
YoY Change	3.61%	-144.06%	-153.04%
FREE CASH FLOW
Cash From Operating Activities	-$1.234M	-$1.177M	-$4.879M
Capital Expenditures	$20.50K	-$50.04K	-$180.6K
Free Cash Flow	-$1.255M	-$1.127M	-$4.699M
YoY Change	13.22%	-3.07%	20.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	lxrp	Weighted Average Exercise Price Beginning Balance WeightedAverageExercisePriceBeginningBalance	16.77
CY2021	lxrp	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	-44161	shares
CY2021	lxrp	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	67.50
CY2021	lxrp	Numbers Of Warrats Exercised NumbersOfWarratsExercised	-610189	shares
CY2021	lxrp	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	6.58
CY2021	lxrp	Numbers Of Warrats Issued NumbersOfWarratsIssued	2630017	shares
CY2021	lxrp	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice	6.58
CY2022	lxrp	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	-25292	shares
CY2022	lxrp	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	4.57
CY2022	lxrp	Weighted Average Exercise Price Ending Balance WeightedAverageExercisePriceEndingBalance	8.04
CY2021	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-22000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	-22000	usd
CY2021	lxrp	Discontinued Operations Change In Working Capital DiscontinuedOperationsChangeInWorkingCapital	2500	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	3000	usd
CY2021	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	3000	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001348362
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5726699	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5950998	shares
CY2021Q3	lxrp	Territory License Fee Receivable TerritoryLicenseFeeReceivable	0	usd
CY2022	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	44851	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022	lxrp	Stock Issued During Period Shares Stock Warrant Exercised StockIssuedDuringPeriodSharesStockWarrantExercised	0	shares
CY2022	lxrp	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	0	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3286274	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2421983	shares
CY2021	lxrp	Life Years LifeYears	P5Y
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-08-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-52138
CY2022	dei	Entity Registrant Name EntityRegistrantName	LEXARIA BIOSCIENCE CORP.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2000871
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	#100 – 740 McCurdy Road
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Kelowna
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2022	dei	Entity Address Country EntityAddressCountry	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V1X 2P7
CY2022	dei	City Area Code CityAreaCode	250
CY2022	dei	Local Phone Number LocalPhoneNumber	765-6424
CY2022	dei	Security12g Title Security12gTitle	Common Stock, Par Value $0.001
CY2022	dei	Trading Symbol TradingSymbol	LEXX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Public Float EntityPublicFloat	21000000	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5950998	shares
CY2022	dei	Auditor Name AuditorName	DAVIDSON & COMPANY LLP
CY2022	dei	Auditor Location AuditorLocation	Vancouver, Canada
CY2022	dei	Auditor Firm AuditorFirmId	731
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5813218	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10917797	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	347335	usd
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	833841	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	201784	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	342401	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	38418	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	29648	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	576761	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	319253	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	6977516	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	12442940	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	52444	usd
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	91041	usd
CY2022Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	488462	usd
CY2021Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	364623	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	315505	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	368213	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	856411	usd
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	823877	usd
CY2022Q3	us-gaap	Assets Assets	7833927	usd
CY2021Q3	us-gaap	Assets Assets	13266817	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	151449	usd
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	105496	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	0	usd
CY2021Q3	us-gaap	Loans Payable Current LoansPayableCurrent	7926	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	42587	usd
CY2021Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	39404	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	194036	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	153276	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7401	usd
CY2021Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	49989	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7401	usd
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	49989	usd
CY2022Q3	us-gaap	Liabilities Liabilities	201437	usd
CY2021Q3	us-gaap	Liabilities Liabilities	203265	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5950998	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5726699	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	5951	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	5727	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47041481	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45089114	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39098528	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31829204	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	7948904	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	13265637	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-316414	usd
CY2021Q3	us-gaap	Minority Interest MinorityInterest	-202085	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7632490	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13063552	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7833927	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13266817	usd
CY2022	us-gaap	Revenues Revenues	255397	usd
CY2021	us-gaap	Revenues Revenues	722738	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	71841	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	175346	usd
CY2022	us-gaap	Gross Profit GrossProfit	183556	usd
CY2021	us-gaap	Gross Profit GrossProfit	547392	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1842675	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1262895	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5724534	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4971349	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	7567209	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	6234244	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-7383653	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5686852	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1522704	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-22000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7383653	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4186148	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7269324	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4027006	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-114329	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159142	usd
CY2022	lxrp	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-1.24
CY2021	lxrp	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.95
CY2022	lxrp	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Shares DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShares	0
CY2021	lxrp	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Shares DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShares	-0.01
CY2022	lxrp	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	5885245	shares
CY2021	lxrp	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	4391446	shares
CY2022	us-gaap	Profit Loss ProfitLoss	7383653	usd
CY2021	us-gaap	Profit Loss ProfitLoss	4186148	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	752591	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	410007	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	102718	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	111718	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2482	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50500	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	38597	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	35879	usd
CY2021	lxrp	Realized Loss On Disposal Of Marketable Securities RealizedLossOnDisposalOfMarketableSecurities	0	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-764614	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-166255	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1522704	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1200000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	85000	usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	usd
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	785895	usd
CY2022	lxrp	Lease Accretion LeaseAccretion	5195	usd
CY2021	lxrp	Lease Accretion LeaseAccretion	7912	usd
CY2022	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	-7926	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	137491	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-189580	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1979	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-95037	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	257508	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	137158	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50726	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13803	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-5223	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-53481	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-44255	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4879339	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3989678	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	131448	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	79493	usd
CY2022	lxrp	Asset Disposition AssetDisposition	-49192	usd
CY2021	lxrp	Asset Disposition AssetDisposition	273373	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-180640	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	193880	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	22744	usd
CY2022	lxrp	Proceed From Payment For Lease Payments ProceedFromPaymentForLeasePayments	44600	usd
CY2021	lxrp	Proceed From Payment For Lease Payments ProceedFromPaymentForLeasePayments	43950	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9471497	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4015043	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-44600	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13419846	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5104579	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9624048	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10917797	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1293749	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5813218	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10917797	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	4782	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	16297	usd
CY2022	lxrp	Marketable Securities Received On Accounts Receivable MarketableSecuritiesReceivedOnAccountsReceivable	278108	usd
CY2021	lxrp	Marketable Securities Received On Accounts Receivable MarketableSecuritiesReceivedOnAccountsReceivable	893493	usd
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2482258	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	85000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	410007	usd
CY2021	lxrp	Warrants Issued For Services WarrantsIssuedForServices	785895	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4015043	usd
CY2021	lxrp	Private Placements Amount PrivatePlacementsAmount	9471497	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4027006	usd
CY2021	lxrp	Net Income Loss Attributable To Noncontrolling Interests NetIncomeLossAttributableToNoncontrollingInterests	-159142	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13063552	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1200000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	752591	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7269324	usd
CY2022	lxrp	Net Income Loss Attributable To Noncontrolling Interests NetIncomeLossAttributableToNoncontrollingInterests	-114329	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7632490	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. Nature of Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or the “Company”) is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“API”) using our proprietary DehydraTECH drug delivery technology. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenues are generated from licensing contracts for the Company’s patented DehydraTECH technology based on the terms of use and defined geographic and licencing arrangements. We derive income from our third party contracted manufacturing of B2B DehydraTECH enhanced products made to customer specifications that are sold online and in-store in the US and Canada. We also perform contract services in R&D for customer specific formulations that are used in comparison testing to customers existing products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Going Concern Consideration</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”) applicable to a going concern which assumes the Company will have sufficient funds to pay it operational, research and development and capital expenditures for a period of at least 12 months from the date this Report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has incurred significant operating and net losses. The losses attributable to shareholders were $7.34m, $4.2m and $4.1m for the years ended August 31, 2022, 2021 and 2020, respectively. As of August 31, 2022, we had an accumulated deficit of $39.1m. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our R&D studies and corporate expenditures, additional revenues received the licencing of our technology, if any, and the receipt of payments under any current or future collaborations we may enter into. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 12, 2021, the Company closed an underwritten public offering with net proceeds of $9,471,497. In the fourth quarter of the year ended August 31, 2021, the Company received $4,015,043 from the exercise of warrants. We did not receive any proceeds from the sale of shares or exercise of convertible securities in the year ended August 31, 2022. We may offer additional securities for sale during our fiscal year 2023 or thereafter in response to market conditions or other circumstances if we believe such a plan of financing is required to advance the Company’s business plans and is in the best interests of our stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern. As of August 31, 2022, the Company had cash and cash equivalents of approximately $5.8m and carries no significant debt other than amounts payable in the short term. We believe this will sufficiently enable the Company to fund its operating and R&D expenses and any capital expenditure requirements through one year from the issuance date of the audited consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Impacts of COVID-19 Pandemic</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The emergence of the COVID-19 pandemic in 2020 continues to present uncertainty and unforecastable new risks to the Company and its business plans. As of August 31, 2022, there has been no material impact on the Company’s financial position as a direct result of the pandemic. However, the Company has experienced some supply chain disruptions and shortages in the timely procurement of ingredients and supplies used in both our R&D activities and B2B production. Management views this situation as transitory but cannot predict the length of time it may take for these disruptions to dissipate or if there will be a significant economic effect on the Company’s operations. In the interim, it may cause delays in carrying out our research studies and in our production schedules.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There may be further actions we must take that alter our operations, including those that may be required by federal, state, provincial, or local authorities, or that we determine are in the best interests of our employees and other third parties with which we do business. We do not know when it will become practical to relax or eliminate some or all these measures entirely. The economic effect of a prolonged pandemic is difficult to predict and could result in material financial impact in the Company’s future reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended August 31, 2020, we were in receipt of C$30,732 in COVID relief under the Canada Emergency Wage Subsidy programs for employees which reduced our employment costs in that year. During fiscal 2020 we also received C$40,000 from the Canadian Government sponsored Emergency Business Account loan program. As specified by the terms of this program, we have repaid C$30,000 of the loan in fiscal 2021. The remaining C$10,000 was forgiven and included as net loss in 2022.</p>
CY2019Q3	lxrp	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	160289	usd
CY2019Q3	lxrp	Operating Lease Liabilities Current OperatingLeaseLiabilitiesCurrent	158773	usd
CY2021Q3	lxrp	Prepaid Licence And Filing Fees Due PrepaidLicenceAndFilingFeesDue	19500	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	80863	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company places its cash with a high credit quality financial institution. As of August 31, 2022, the Company had approximately $5.8m on deposit. (August 31, 2021: $10.9m). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the year ended August 31, 2022, one licensee accounted for 100% (2021 – 72%) of revenues. At fiscal year end 2022, we had $37,248 (2021 - $Nil) in licence fees receivable. The Company incurred a bad debt in fiscal 2021 ($50,500) primarily due to cancellations of IP license agreements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As at August 31, 2022, the Company had $84,162 (2021 - $47,741) in sales tax receivable. The Company considers its credit risk to be low for such receivables.</p>
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5800000	usd
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	10900000	usd
CY2022	lxrp	Licensee Accounted Revenues LicenseeAccountedRevenues	1	pure
CY2021	lxrp	Licensee Accounted Revenues LicenseeAccountedRevenues	0.72	pure
CY2022Q3	lxrp	Territory License Fee Receivable TerritoryLicenseFeeReceivable	37248	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50500	usd
CY2022Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	84162	usd
CY2021Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	47741	usd
CY2021	us-gaap	Adjustment For Long Term Intercompany Transactions Tax Expense Benefit AdjustmentForLongTermIntercompanyTransactionsTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1271207	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1006256	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	201784	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	342401	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	38418	usd
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	29648	usd
CY2022Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	359863	usd
CY2021Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	168760	usd
CY2022Q3	lxrp	Consulting Consulting	0	usd
CY2021Q3	lxrp	Consulting Consulting	18750	usd
CY2022Q3	lxrp	Prepaid Legal Fees PrepaidLegalFees	25000	usd
CY2021Q3	lxrp	Prepaid Legal Fees PrepaidLegalFees	31380	usd
CY2022Q3	lxrp	Prepaid Licence And Filing Fees Due PrepaidLicenceAndFilingFeesDue	15000	usd
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	80863	usd
CY2022Q3	us-gaap	Capital Capital	96035	usd
CY2021Q3	us-gaap	Capital Capital	0	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	576761	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	319253	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6093	usd
CY2022	lxrp	Balance Beginning BalanceBeginning	364623	usd
CY2021	lxrp	Balance Beginning BalanceBeginning	292000	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	131448	usd
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	79493	usd
CY2022	lxrp	Amortization Of Intellectual Assets AmortizationOfIntellectualAssets	-7609	usd
CY2021	lxrp	Amortization Of Intellectual Assets AmortizationOfIntellectualAssets	-6870	usd
CY2022	lxrp	Balance Ending BalanceEnding	488462	usd
CY2021	lxrp	Balance Ending BalanceEnding	364623	usd
CY2022Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	646306	usd
CY2022	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	49192	usd
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	379993	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	315505	usd
CY2021Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	649400	usd
CY2021	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	0	usd
CY2021	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	3094	usd
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	278093	usd
CY2021Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	368213	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	3655	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	10926	usd
CY2021	lxrp	Operating Segment Expenses OperatingSegmentExpenses	-4711523	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4164131	usd
CY2021Q3	us-gaap	Assets Net AssetsNet	13266817	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	151449	usd
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	105946	usd
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5223000	usd
CY2022	lxrp	Income From Ongoing Operations IncomeFromOngoingOperations	255397	usd
CY2021	lxrp	Income From Ongoing Operations IncomeFromOngoingOperations	722738	usd
CY2022	lxrp	Product Revenues ProductRevenues	113438000	usd
CY2021	lxrp	Product Revenues ProductRevenues	383179000	usd
CY2022	lxrp	Licensing Usage LicensingUsage	54560000	usd
CY2021	lxrp	Licensing Usage LicensingUsage	334974000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7383653	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4169832	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1619854	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-800952	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-280155	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-142895	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-44867	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-56316	usd
CY2022	us-gaap	Adjustment For Long Term Intercompany Transactions Tax Expense Benefit AdjustmentForLongTermIntercompanyTransactionsTaxExpenseBenefit	23625	usd
CY2022Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7747485	usd
CY2021Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	6580183	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	118175	usd
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	14270	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7865660	usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6594453	usd
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	36387000	usd
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	36387000	usd
CY2022	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	224299	shares
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1200000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	25292	shares
CY2022	lxrp	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0	usd
CY2022	lxrp	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	0	usd
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	224499	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1200000	usd
CY2022	lxrp	Number Of Shares Issued Under Exercise Of Options And Private Placement And Per Agreements NumberOfSharesIssuedUnderExerciseOfOptionsAndPrivatePlacementAndPerAgreements	224499	shares
CY2022	lxrp	Value Of Shares Issued Under Exercise Of Options And Private Placement And Per Agreements ValueOfSharesIssuedUnderExerciseOfOptionsAndPrivatePlacementAndPerAgreements	1200000	usd
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	471608	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2447275	shares
CY2021	lxrp	Weighted Average Exercise Price Ending Balance WeightedAverageExercisePriceEndingBalance	8.00
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2421983	shares
CY2022	lxrp	Schedule Of Fair Value Percentage Of Share Purchase Warrants Black Scholes Pricing Model ScheduleOfFairValuePercentageOfSharePurchaseWarrantsBlackScholesPricingModel	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>August 31</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>August 31</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Expected volatility</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risk-free interest rate</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.16</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Expected life</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Dividend yield</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Estimated fair value per warrant</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6.51</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5175	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	401333	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.57
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M28D
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2421983	shares
CY2022	lxrp	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P3Y14D
CY2022Q3	lxrp	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	8.04
CY2022	lxrp	Number Of Stock Options Granted NumberOfStockOptionsGranted	261290	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	During the Company’s 2021 Annual Meeting of Shareholders, shareholders voted in favour of increasing the number of allowable stock options by an additional 249,143 options. The aggregate number of shares issuable under the Equity Incentive Plan is 510,433 shares, representing 10% of the Company’s issued share capital
CY2022	lxrp	Life Years LifeYears	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	222000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.21
CY2022	lxrp	Life Years LifeYears	P5Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	84900	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.41
CY2021	lxrp	Number Of Stock Options Granted NumberOfStockOptionsGranted	87935	shares
CY2021	us-gaap	Option Indexed To Issuers Equity Strike Price1 OptionIndexedToIssuersEquityStrikePrice1	7.08
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	171604	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.17
CY2021	lxrp	Outstanding Options Or Rights Expired Cancelled OutstandingOptionsOrRightsExpiredCancelled	-50344	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.76
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	161600	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.41
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	206170	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.90
CY2022	lxrp	Outstanding Options Or Rights Expired Cancelled OutstandingOptionsOrRightsExpiredCancelled	-3334	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.60
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	222000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.21
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	424836	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.45
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M8D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5175	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98	pure
CY2022	lxrp	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate65 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate65	1.19	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.33	pure
CY2021	lxrp	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate65 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate65	1.34	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0078	pure
CY2022	lxrp	Risk Free Interest Rate Maximum RiskFreeInterestRateMaximum	0.0330	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0042	pure
CY2021	lxrp	Risk Free Interest Rate Maximum RiskFreeInterestRateMaximum	0.0085	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.25
CY2022Q3	lxrp	Estimated Fair Value Per Option Maximum EstimatedFairValuePerOptionMaximum	5.10
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	4.00
CY2021Q3	lxrp	Estimated Fair Value Per Option Maximum EstimatedFairValuePerOptionMaximum	4.86
CY2022	lxrp	Right Of Use Assets Operating Leases RightOfUseAssetsOperatingLeases	91041	usd
CY2021	lxrp	Right Of Use Assets Operating Leases RightOfUseAssetsOperatingLeases	126920	usd
CY2022	lxrp	Amortization Of Lease Asset AmortizationOfLeaseAsset	38597	usd
CY2021	lxrp	Amortization Of Lease Asset AmortizationOfLeaseAsset	35879	usd
CY2022	lxrp	Lease Assets LeaseAssets	52444	usd
CY2021	lxrp	Lease Assets LeaseAssets	91041	usd
CY2022	lxrp	Operating Lease Liabilities OperatingLeaseLiabilities	89393	usd
CY2021	lxrp	Operating Lease Liabilities OperatingLeaseLiabilities	125431	usd
CY2022	lxrp	Lease Payments LeasePayments	-44600	usd
CY2021	lxrp	Lease Payments LeasePayments	-43950	usd
CY2022	lxrp	Operatingleaseinterest Accretion OperatingleaseinterestAccretion	5195	usd
CY2021	lxrp	Operatingleaseinterest Accretion OperatingleaseinterestAccretion	7912	usd
CY2022	lxrp	Lease Liabilities Operating Lease LeaseLiabilitiesOperatingLease	49988	usd
CY2021	lxrp	Lease Liabilities Operating Lease LeaseLiabilitiesOperatingLease	89393	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	52444	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	91041	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	44599	usd
CY2021	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	43950	usd
CY2022	lxrp	Remaining Lease Term RemainingLeaseTerm	P1Y2M1D
CY2021	lxrp	Remaining Lease Term RemainingLeaseTerm	P2Y1M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0725	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0725	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	44815	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7469	usd
CY2022Q2	lxrp	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	0	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	52284	usd
CY2022Q2	lxrp	Operating Imputed Interest OperatingImputedInterest	-2296	usd
CY2022Q2	lxrp	Present Value Of Operating Lease Liabilities PresentValueOfOperatingLeaseLiabilities	49988	usd
CY2022Q2	lxrp	Less Current Obligations Under Leases LessCurrentObligationsUnderLeases	42587	usd
CY2022Q2	lxrp	Operating Lease Liability Non Current Amount OperatingLeaseLiabilityNonCurrentAmount	7401	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	255397	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	71841	usd
CY2022	lxrp	Operating Segment Expenses OperatingSegmentExpenses	-7567209	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7383653	usd
CY2022Q3	us-gaap	Assets Net AssetsNet	7833927	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	722738	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	175346	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	315505	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	368213	usd
CY2021Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	5882353	shares
CY2021Q3	us-gaap	Stock Issued1 StockIssued1	390533	usd
CY2021Q3	lxrp	Allotment Share AllotmentShare	1693405	shares
CY2021Q3	lxrp	Allotment Share Value AllotmentShareValue	122426	shares
CY2022Q2	lxrp	Tranche Share Received TrancheShareReceived	4188948	shares
CY2022Q3	lxrp	Book Value Of Assets Sold BookValueOfAssetsSold	0	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	273373	usd
CY2022	lxrp	Shares Received On Disposal Of Asset SharesReceivedOnDisposalOfAsset	1249331	usd
CY2022	lxrp	Promissory Note Received On Disposal Of Asset PromissoryNoteReceivedOnDisposalOfAsset	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1522704	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	25000	usd

Files In Submission

Name	View Source	Status
0001640334-22-002512-index-headers.html	Edgar Link	pending
lxrp-20220831_cal.xml	Edgar Link	unprocessable
0001640334-22-002512-index.html	Edgar Link	pending
0001640334-22-002512.txt	Edgar Link	pending
0001640334-22-002512-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrp-20220831.xsd	Edgar Link	pending
lxrp_10k.htm	Edgar Link	pending
lxrp_10kimg2.jpg	Edgar Link	pending
lxrp_10kimg3.jpg	Edgar Link	pending
lxrp_ex231.htm	Edgar Link	pending
lxrp_ex231img2.jpg	Edgar Link	pending
lxrp_ex231img3.jpg	Edgar Link	pending
lxrp_ex311.htm	Edgar Link	pending
lxrp_ex312.htm	Edgar Link	pending
lxrp_ex321.htm	Edgar Link	pending
lxrp_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
lxrp-20220831_lab.xml	Edgar Link	unprocessable
lxrp-20220831_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
lxrp-20220831_pre.xml	Edgar Link	unprocessable
lxrp_10k_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LEXX
Lexaria Bioscience Corp. Stock $lexx

2022 Q4 Form 10-K Financial Statement

#000164033422002512 Filed on November 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX Lexaria Bioscience Corp. Stock $lexx

2022 Q4 Form 10-K Financial Statement

#000164033422002512 Filed on November 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX
Lexaria Bioscience Corp. Stock $lexx